IMPORTANT REGULUS THERAPEUTICS INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the Southern District of California against Regulus Therapeutics Inc.

NEW YORK and SAN DIEGO, Feb. 09, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP  announces  that  a  class  action  lawsuit  has  been  filed  against  Regulus Therapeutics Inc. (“Regulus”  or the  “Company”) (NASDAQ:RGLS)  in the  United States District Court  for the Southern  District of California  on behalf  of persons or entities who purchased or otherwise acquired Regulus stock  between January 21, 2016 and June 27, 2016, inclusive (the “Class Period”).

Investors who have incurred losses in shares of  Regulus Therapeutics Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If   you have purchased  shares of Regulus Therapeutics Inc. within  the class period, you may, no later than April 3, 2017, request that the Court appoint you lead plaintiff of the proposed class.

The filed Complaint alleges that Defendants made false and/or misleading  statements and/or failed  to disclose  that: (1)  patients treated  with RG-101  were  at increased risk  of contracting  jaundice; (2)  consequently, the  Company  had overstated RG-101’s approval prospects and/or commercial viability; and (3) as a result of the foregoing,  Regulus’s public statements were materially  false and misleading at all relevant times.

On June 27, 2016, the Company  announced that it  had received verbal  notice from the United States Food and Drug  Administration (“FDA”) that  the FDA had  placed RG-101 on clinical hold after a  second serious adverse event of jaundice  was reported in a  patient treated with  the drug.   

On this news, the   Company’s share price fell $2.47, or more than 49%, to close at $2.54 on June 28, 2016.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.

Follow the firm and learn about newly filed cases on Twitter and Facebook.

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP 
Patrick Donovan, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774